001     296085
005     20250103121049.0
024 7 _ |a 10.1016/j.lungcan.2024.108072
|2 doi
024 7 _ |a pmid:39740425
|2 pmid
024 7 _ |a 0169-5002
|2 ISSN
024 7 _ |a 1872-8332
|2 ISSN
037 _ _ |a DKFZ-2025-00033
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Aguado-Barrera, Miguel E
|b 0
245 _ _ |a Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1735825548_23499
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies.Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses.We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91).Our findings indicate strong alignment between healthcare professionals' and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Correlation measures
|2 Other
650 _ 7 |a Fatigue
|2 Other
650 _ 7 |a Lung cancer
|2 Other
650 _ 7 |a Patient reported outcome measures
|2 Other
650 _ 7 |a Quality of life
|2 Other
650 _ 7 |a Radiation effects
|2 Other
650 _ 7 |a Symptom assessment
|2 Other
700 1 _ |a Lopez-Pleguezuelos, Carlos
|b 1
700 1 _ |a Gómez-Caamaño, Antonio
|b 2
700 1 _ |a Calvo-Crespo, Patricia
|b 3
700 1 _ |a Taboada-Valladares, Begoña
|b 4
700 1 _ |a Azria, David
|b 5
700 1 _ |a Boisselier, Pierre
|b 6
700 1 _ |a Briers, Erik
|b 7
700 1 _ |a Chan, Clara
|b 8
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 9
|u dkfz
700 1 _ |a Coedo-Costa, Carla
|b 10
700 1 _ |a Crujeiras-González, Ana
|b 11
700 1 _ |a Cuaron, John J
|b 12
700 1 _ |a Defraene, Gilles
|b 13
700 1 _ |a Elliott, Rebecca M
|b 14
700 1 _ |a Faivre-Finn, Corinne
|b 15
700 1 _ |a Franceschini, Marzia
|b 16
700 1 _ |a Fuentes-Rios, Olivia
|b 17
700 1 _ |a Galego-Carro, Javier
|b 18
700 1 _ |a Gutiérrez-Enríquez, Sara
|b 19
700 1 _ |a Heumann, Philipp
|0 P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753
|b 20
|u dkfz
700 1 _ |a Higginson, Daniel S
|b 21
700 1 _ |a Johnson, Kerstie
|b 22
700 1 _ |a Lambrecht, Maarten
|b 23
700 1 _ |a Lang, Philippe
|b 24
700 1 _ |a Lievens, Yolande
|b 25
700 1 _ |a Mollà, Meritxell
|b 26
700 1 _ |a Ramos, Mónica
|b 27
700 1 _ |a Rancati, Tiziana
|b 28
700 1 _ |a Rattay, Tim
|b 29
700 1 _ |a Rimner, Andreas
|b 30
700 1 _ |a Rosenstein, Barry S
|b 31
700 1 _ |a Sangalli, Claudia
|b 32
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 33
|u dkfz
700 1 _ |a Sperk, Elena
|b 34
700 1 _ |a Stobart, Hilary
|b 35
700 1 _ |a Symonds, Paul
|b 36
700 1 _ |a Talbot, Christopher J
|b 37
700 1 _ |a Vandecasteele, Katrien
|b 38
700 1 _ |a Veldeman, Liv
|b 39
700 1 _ |a Ward, Tim
|b 40
700 1 _ |a Webb, Adam
|b 41
700 1 _ |a Woolf, David
|b 42
700 1 _ |a de Ruysscher, Dirk
|b 43
700 1 _ |a West, Catharine M L
|b 44
700 1 _ |a Vega, Ana
|b 45
700 1 _ |a Consortium, REQUITE
|b 46
|e Collaboration Author
773 _ _ |a 10.1016/j.lungcan.2024.108072
|g Vol. 199, p. 108072 -
|0 PERI:(DE-600)2025812-4
|p 108072
|t Lung cancer
|v 199
|y 2025
|x 0169-5002
909 C O |o oai:inrepo02.dkfz.de:296085
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LUNG CANCER : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b LUNG CANCER : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21